ClinicalTrials.Veeva

Menu

Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study

Kansas City Heart Rhythm Research Foundation logo

Kansas City Heart Rhythm Research Foundation

Status

Enrolling

Conditions

Hemostasis
Atrial Fibrillation

Treatments

Device: Vascular closure with LockeT device

Study type

Interventional

Funder types

Other

Identifiers

NCT06078735
KCHRRF_LockeT II_0023

Details and patient eligibility

About

The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.

Full description

The volume of catheter ablation procedures for the treatment of atrial fibrillation and other arrhythmias are on the rise in the United States and worldwide. Despite decrease in complication rates due to refinement in ablation tools and techniques, achieving vascular hemostasis following large-bore sheath femoral access remains a challenge. Thus, MC remains the current standard of care. However, MC requires up to 8 hours of prolonged bedrest, which is associated with longer length of stay and complications from indwelling catheters.

Another method of vascular closure is the figure-of-eight (FoE) stitch - a subcutaneous suture that has been evaluated to achieve homeostasis following major cardiovascular procedures.

In recent years, invasive, vascular closure devices have become popular. However, results continue to suggest that the risk versus benefit has not been definitively demonstrated. Instead, the LockeT is a new suture retention device designed to closely mimic manual compression by distributing the tension of a FoE stitch over a larger surface area. In such a way, patients can have the benefits of MC without a healthcare professional to stand bedside.

Enrollment

110 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must be at least 18 years of age
  • Be able to provide consent
  • Presenting for planned procedures that require percutaneous venous punctures, such as atrial fibrillation radiofrequency ablation, and where the physician utilizes a LockeT device or MC to close the wound.

Exclusion criteria

  • Under the age of 18
  • Unable to or unwilling to provide consent
  • Cannot comply with study requirements
  • Not undergoing procedures that require a percutaneous venous puncture or planned access to the left atrium and/or ventricle
  • Subjects whose physician does not use LockeT or MC to close the venous puncture.
  • Patient is currently pregnant, as evidenced by positive urine Beta-HCG. (Urine Beta Human chorionic gonadotropin (HCG) will be checked in all females of the reproductive age group).
  • If the physician detects a formed hematoma prior to venous closure, that patient will be excluded from the study.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

110 participants in 2 patient groups

LockeT
Experimental group
Description:
These are the patients assigned for LockeT device arm to close the access site wound.
Treatment:
Device: Vascular closure with LockeT device
Manual compression
No Intervention group
Description:
These are the patients assigned for Manual Compression arm to close the access site wound.

Trial contacts and locations

6

Loading...

Central trial contact

Donita Atkins

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems